Amgen and Zai Lab have agreed to run a global clinical trial combining two DLL3 targeted therapies for small cell lung cancer ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen (AMGN) is drawing fresh attention after Phase 3 data for subcutaneous TEPEZZA in Thyroid Eye Disease and strong weight ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Amgen Inc. (NASDAQ:AMGN) is one of the 7 Most Profitable Value Stocks to Buy Right Now. Amgen Inc. (NASDAQ:AMGN) is one of ...

The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall ...

SHANGHAI, April 10 (Reuters) - Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines ...

Amgen has performed decently but it’s best returns are still ahead.

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

Zai Lab (ZLAB) stock jumps as the company announces a global clinical trial collaboration with Amgen (AMGN). Read more here.